Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins CA, Parsley E, Aranda R, Zisman LS, Ghofrani HA; TORREY Study Investigators. Frantz RP, et al. Among authors: bruey jm. Lancet Respir Med. 2024 Jul;12(7):523-534. doi: 10.1016/S2213-2600(24)00072-9. Epub 2024 May 2. Lancet Respir Med. 2024. PMID: 38705167 Clinical Trial.
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity.
Liu X, Hogg GD, Zuo C, Borcherding NC, Baer JM, Lander VE, Kang LI, Knolhoff BL, Ahmad F, Osterhout RE, Galkin AV, Bruey JM, Carter LL, Mpoy C, Vij KR, Fields RC, Schwarz JK, Park H, Gupta V, DeNardo DG. Liu X, et al. Among authors: bruey jm. Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12. doi: 10.1016/j.ccell.2023.04.018. Epub 2023 May 25. Cancer Cell. 2023. PMID: 37236195 Free PMC article.
Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.
Moss MH, Lugogo NL, Castro M, Hanania NA, Ludwig-Sengpiel A, Saralaya D, Dobek R, Ojanguren I, Vyshnyvetskyy I, Bruey JM, Osterhout R, Tompkins CA, Dittrich K, Raghupathi K, Ortega H; LEDA Investigators. Moss MH, et al. Among authors: bruey jm. Chest. 2022 Aug;162(2):297-308. doi: 10.1016/j.chest.2022.02.038. Epub 2022 Mar 3. Chest. 2022. PMID: 35248549 Free article. Clinical Trial.
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Meadows KT, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Danese S, et al. Among authors: bruey jm. Aliment Pharmacol Ther. 2022 Mar;55(6):735-736. doi: 10.1111/apt.16795. Aliment Pharmacol Ther. 2022. PMID: 35245951 No abstract available.
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis.
Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Danese S, et al. Among authors: bruey jm. Aliment Pharmacol Ther. 2022 Feb;55(4):401-411. doi: 10.1111/apt.16753. Epub 2022 Jan 10. Aliment Pharmacol Ther. 2022. PMID: 35014040 Free PMC article. Clinical Trial.
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension.
Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, Sitbon O, Zamanian RT, Hemnes AR, Cravets M, Bruey JM, Roscigno R, Mottola D, Elman E, Zisman LS, Ghofrani HA. Frantz RP, et al. Among authors: bruey jm. Pulm Circ. 2021 Nov 11;11(4):20458940211057071. doi: 10.1177/20458940211057071. eCollection 2021 Oct-Dec. Pulm Circ. 2021. PMID: 34790348 Free PMC article.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Vennapusa B, et al. Among authors: bruey jm. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594. Appl Immunohistochem Mol Morphol. 2019. PMID: 29346180 Free PMC article.
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D. Shah MA, et al. Among authors: bruey jm. JAMA Oncol. 2017 May 1;3(5):620-627. doi: 10.1001/jamaoncol.2016.5580. JAMA Oncol. 2017. PMID: 27918764 Free PMC article. Clinical Trial.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS. Cloughesy T, et al. Among authors: bruey jm. J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5. J Clin Oncol. 2017. PMID: 27918718 Clinical Trial.
33 results